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Combined effect of sodium–glucose
cotransporter 2 and dipeptidyl peptidase-4
inhibitors for diabetic kidney disease
The aim of diabetes treatment is to
maintain quality of life and to extend
healthy longevity to the same extent as
those for healthy people. To achieve this
aim, it is important to prevent the pro-
gression of diabetic vascular complica-
tions. In particular, diabetic kidney
disease (DKD) – mainly in individuals
with type 2 diabetes – is a leading cause
of end-stage renal disease worldwide.
Among patients with type 2 diabetes, the
progression of DKD markedly increases
the risk for other vascular complications,
resulting in increased medical care costs
related to diabetes treatment. Thus,
appropriate management of DKD is clin-
ically and societally relevant in improving
prognosis.
DKD is characterized by an increase
in albuminuria and a decrease in the
glomerular ﬁltration rate (GFR). Increases
in albuminuria lead to a higher risk for
progression to end-stage renal disease,
whereas a reduction in albuminuria is
associated with slower deterioration in
kidney function accompanied by reduced
risk for the onset of macrovascular com-
plications and mortality. Thus, treatment
aimed at reducing albuminuria is an
important component of therapeutic
strategies aimed at improving prognosis
in patients with DKD. Presently, compre-
hensive risk management addressing life-
style habits and risk factors, including
hyperglycemia, hypertension and dyslipi-
demia, is emphasized with regard to pre-
venting the onset and the progression of
DKD1. However, strict pharmacological
treatment for these risk factors might
increase the incidence of adverse effects,
such as severe hypoglycemia.
In particular, special considerations for
the selection of glucose-lowering medica-
tion(s) in patients with DKD are
required, owing to an increased risk for
adverse effects as a result of reduced kid-
ney function (Table 1). Glucose-lowering
drugs, which are cleared by the kidney,
require renal dosing adjustment in
patients with an estimated GFR (eGFR)
<60 mL/min/1.73 m2. While administer-
ing these drugs, kidney function should
be carefully monitored, and the efﬁcacy
and risk of continuing treatment must be
continually reviewed. Furthermore, most
of these drugs are contraindicated in
those with severely impaired kidney
function, such as those with an eGFR
<30 mL/min/1.73 m2. For example, met-
formin, which is the recommended initial
medication for lowering glucose levels in
patients with type 2 diabetes, is con-
traindicated in those with an eGFR
<30 mL/min/1.73 m2, owing to an
increased risk for lactic acidosis2.
Among glucose-lowering medications,
some are reported to exert a direct reno-
protective effect. Recent large randomized
controlled trials reported that sodium–
glucose cotransporter 2 (SGLT2) inhibi-
tors are effective for reducing the risk for
all-cause mortality and cardiovascular
morbidity, and maintaining kidney func-
tion in individuals with type 2 diabetes
and preserved kidney function3. The
principle pharmacological action of
SGLT2 inhibitors is to inhibit the reab-
sorption of glucose and sodium at the
proximal tubules of the kidney, resulting
in lower blood glucose levels and reduced
bodyweight. In addition to their glucose-
lowering effect, SGLT2 inhibitors are
reported to exert numerous osmotic and
natriuretic effects, such as decreased sys-
temic blood pressure, intraglomerular
pressure, albuminuria and uric acid
levels, and increased hematocrit, among
others. These multifactorial metabolic
and hemodynamic actions most likely
cooperatively contribute to renal protec-
tion. However, the glucose-lowering effect
of SGLT2 inhibitors is attenuated accord-
ing to worsening kidney function,
whereas other renoprotective effects
appear to be independent of kidney func-
tion4. Thus, exploring which glucose-low-
ering medication(s) should be added if
appropriate glycemic control is not
Table 1 | Disadvantages of oral antihyperglycemic agents in patients with type 2 diabetes and
reduced kidney function
Class Disadvantage with reduced kidney function
Biguanides Increased risk for lactic acidosis
Sulfonylureas Increased risk for severe hypoglycemia
Meglinitides Hypoglycemia
a-Glucosidase inhibitors Gastrointestinal problems including abdominal discomfort, diarrhea
and flatulence
Thiazolidinediones Increased risk for fluid retention and edema
DPP-4 inhibitors Relatively safe; however, some are required renal dosing adjustment
SGLT2 inhibitors Attenuated glucose-lowering effect
DPP-4, dipeptidyl peptidase-4; SGLT2, sodium–glucose cotransporter 2.
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achieved in individuals with type 2 dia-
betes and reduced kidney function trea-
ted with SGLT2 inhibitors is an
important clinical issue.
Dipeptidyl peptidase-4 (DPP-4) inhibi-
tors are also novel glucose-lowering
agents. The pharmacological action of
DPP-4 inhibitors is to inhibit the break-
down of glucagon-like peptide-1, which
is different from the glucose-lowering
mechanism of SGLT2 inhibitors. In clini-
cal practice, DPP-4 inhibitors are widely
used, because they confer a low risk for
hypoglycemia unless they are adminis-
tered with drugs that are associated with
hypoglycemia, such as insulin and
sulphonylureas. Furthermore, the advan-
tage of DPP-4 inhibitors is that they can
be used relatively safely and effectively
for lowering glucose levels in patients
with reduced kidney function, even in
those undergoing maintenance hemodial-
ysis, although some DPP-4 inhibitors
need dose adjustment as kidney function
declines. Additionally, some DPP-4 inhi-
bitors have been reported to reduce albu-
minuria in some clinical trials. With
increasing evidence supporting a role of
SGLT2 and DPP-4 inhibitors in type 2
diabetes, combination therapies of these
drugs are now available in clinical prac-
tice, and have been shown to act in a
complementary, synergistic manner to
reduce glycated hemoglobin A1c
(HbA1c) levels more than that achieved
with either agent as monotherapy. How-
ever, it remains unclear whether this
combination therapy is renoprotective in
patients with type 2 diabetes and DKD,
as well as its glucose-lowering effects.
The albuminuria-lowering effect of
dapagliﬂozin alone and in combination
with saxagliptin, and the effect of dapa-
gliﬂozin and saxagliptin on glycemic con-
trol in patients with type 2 diabetes and
chronic kidney disease (DELIGHT) trial,
published in Lancet Diabetes Endocrinol-
ogy, was the ﬁrst prospective clinical trial
to evaluate the efﬁcacy and safety of
combination therapy of an SGLT2 inhibi-
tor (dapagliﬂozin) and DPP-4 inhibitor
(saxagliptin) in regard to a reduction in
albuminuria and HbA1c in patients with
type 2 diabetes and established DKD5.
This trial was a randomized, double-
blind, placebo-controlled clinical study
including 448 patients with type 2 dia-
betes, urine albumin-to-creatinine ratio
(UACR) 30–3,500 mg/g Cr and eGFR of
20–80 mL/min/1.73 m2 who were under-
going stable glucose-lowering and antihy-
pertensive treatments, including renin–
angiotensin system blockers. Participants
were randomly assigned to receive a pla-
cebo, dapagliﬂozin alone or combination
therapy of dapagliﬂozin and saxagliptin,
and followed for 24 weeks. The primary
end-point for the dapagliﬂozin
monotherapy group was the percentage
change in UACR at 24 weeks and, for
the combination therapy group, the per-
centage change in UACR and HbA1c at
week 24 versus baseline. Compared with
the placebo, dapagliﬂozin monotherapy
and combination therapy of dapagliﬂozin
and saxagliptin signiﬁcantly reduced
UACR by 21% and 38%, respectively,
after 24 weeks of treatment. A reduction
of HbA1c in the combination therapy
group was also observed throughout the
intervention period, and the difference
versus the placebo at week 24 was -
0.58% (P < 0.0001). Additionally, the dif-
ference in changes in UACR was consis-
tent, without regard to the responses of
HbA1c, bodyweight or blood pressure
responses. Importantly, combination
therapy with dapagliﬂozin and saxagliptin
was well tolerated by patients with severe
kidney dysfunction.
The results of the DELIGHT trial
showed that combination therapy with
SGLT2 and DPP-4 inhibitors is an
attractive therapeutic option to concomi-
tantly and effectively achieve the dual
objectives of glucose lowering and albu-
minuria reduction in patients with DKD,
although this trial had some limitations,
including a short trial period and small
sample size. Similar to previous reports,
an initial decrease in eGFR was observed,
both with dapagliﬂozin monotherapy and
combination therapy with dapagliﬂozin
and saxagliptin, which was completely
reversible after treatment discontinuation.
However, this trial could not provide
information as to whether the combina-
tion therapy delayed progression to end-
stage renal disease because of the short
trial period. Furthermore, it remains
unclear as to whether combination ther-
apy with SGLT2 and DPP-4 inhibitors is
effective and safe in patients with more
severe kidney dysfunction (eGFR
<20 mL/min/1.73 m2), and those with
normoalbuminuric DKD who might
have the condition due to cause(s) other
than diabetes per se. The mechanism by
which this combination therapy more
effectively reduces albuminuria in
patients with type 2 diabetes and DKD
remains to be fully elucidated.
At the same time, the Canagliﬂozin
and Renal Endpoints in Diabetes with
Established Nephropathy Clinical Evalua-
tion (CREDENCE) study was published6.
The CREDENCE study showed that
canagliﬂozin (an SGLT2 inhibitor) is
effective for risk reduction of renal com-
posite outcome in type 2 diabetes
patients with UACR >300 mg/g and an
eGFR of 30–90 mL/min/1.73 m2. Unfor-
tunately, the CREDENCE study did not
report data regarding renoprotective
effect(s) and safety of concomitant anti-
hyperglycemic treatments, although
patients taking DPP-4 inhibitors (approx-
imately 17%) were included at baseline.
Thus, in the CREDENCE study, it
remains unclear which glucose-lowering
drug combined with SGLT2 inhibitors
was more effective and safer in patients
with DKD. At the minimum, these two
trials – DELIGHT and CREDENCE –
conﬁrmed and extended previous ﬁnd-
ings that SGLT2 inhibitors exert a reno-
protective effect in patients with type 2
diabetes and moderate-to-severe kidney
dysfunction.
There is little doubt that the develop-
ment of novel therapeutic options for
individuals with type 2 diabetes and
DKD has made it possible to provide
high-quality diabetes care to those with
DKD. However, it remains difﬁcult to
achieve appropriate comprehensive risk
management safely and to maintain kid-
ney function in those with DKD.
According to the progression of DKD,
the use of many glucose-lowering drugs
is restricted, which makes it increasingly
difﬁcult to achieve appropriate glycemic
2 J Diabetes Investig Vol.  No.   2019 ª 2019 The Author. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd
C OMMEN T A R Y
Araki http://wileyonlinelibrary.com/journal/jdi
control safely. Thus, it is clinically impor-
tant to explore therapeutic options that
can help individuals with type 2 diabetes
and DKD achieve better health out-
comes.
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